PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
242.97%
Revenue growth above 1.5x ACB.TO's 82.58%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
191.95%
Gross profit growth at 50-75% of ACB.TO's 299.28%. Martin Whitman would question if cost structure or brand is lagging.
-318.21%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-318.21%
Negative operating income growth while ACB.TO is at 28.32%. Joel Greenblatt would press for urgent turnaround measures.
-299.52%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-295.00%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-295.00%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
2.15%
Share reduction more than 1.5x ACB.TO's 10.25%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.34%
Diluted share reduction more than 1.5x ACB.TO's 12.28%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-1249.62%
Negative OCF growth while ACB.TO is at 7.50%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-27.33%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
28238.49%
5Y CAGR of 28238.49% while ACB.TO is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
545.67%
3Y CAGR of 545.67% while ACB.TO is zero. Bruce Berkowitz would see if small gains can accelerate to a more decisive lead.
-187.04%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-89.89%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-395.23%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-1405.06%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-592.17%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-1081.80%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
4146.76%
10Y equity/share CAGR 1.25-1.5x ACB.TO's 3743.61%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
2334.22%
Below 50% of ACB.TO's 11262.48%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
298.88%
Below 50% of ACB.TO's 10373.21%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
37.94%
AR growth well above ACB.TO's 38.87%. Michael Burry fears inflated revenue or higher default risk in the near future.
115.87%
Inventory growth well above ACB.TO's 12.31%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-1.21%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-5.72%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
41.69%
Debt growth far above ACB.TO's 19.39%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-63.20%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
90.27%
We expand SG&A while ACB.TO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.